Pharmabiz13h
DFE Pharma expands its C2F Center of Excellence in Hyderabad to advance the development of critical respiratory treatments
DFE Pharma, a global leader in pharmaceutical and biopharmaceutical excipient solutions, has expanded the capabilities of its Closer to the Formulator (C2F) Center of Excellence located in Genome ...
Pharmabiz7h
Telix to buy next-generation therapeutic assets and innovative biologics technology platform from ImaginAb
Telix, a commercial-stage biopharmaceutical company, announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next ...
Pharmabiz9h
Illumina launches pilot proteomics programme with UK Biobank and biopharma collaborators to analyze 50,000 samples
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced a pilot proteomics programme to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, ...
Pharmabiz5h
Telix enters agreement with Curium Pharma for transfer of marketing and distribution rights for Scintimun
Telix, a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals, announces that it has entered ...
Pharmabiz3d
NPPA recalculates ceiling price of azithromycin 250 mg following review order
The National Pharmaceutical Pricing Authority (NPPA) has released the revised calculation sheet for the ceiling price of azithromycin 250 mg tablet following a review order from the Department of ...
Pharmabiz3d
Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology
Boehringer Ingelheim and Synaffix B.V. (Synaffix), a Lonza company focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug conjugates (ADCs ...
Pharmabiz3d
Astellas Pharma announces US FDA confirms Class 1 resubmission of the sNDA for Izervay for geographic atrophy
Astellas Pharma Inc. announced the US Food and Drug Administration (FDA) accepted the revised supplemental New Drug Application (sNDA) for Izervay (avacincaptad pegol intravitreal solution) for the ...
Pharmabiz3d
US FDA grants priority review status to Johnson & Johnson’s nipocalimab BLA to treat generalized myasthenia gravis
Johnson & Johnson announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the US Food and Drug Administration (FDA) for the treatment of antibody ...
Pharmabiz3d
Seven research leaders awarded prestigious NIHR award
The NIHR has announced the latest outstanding researchers to become NIHR Research Professors. They will play a key role in undertaking professorial-level research that has a positive impact on the ...
Pharmabiz3d
Gaelic Labs establishes subsidiary in UAE, enabling access to growing Middle East pharma market
Gaelic Laboratories, a European CMO based in Ireland, has established a subsidiary in the UAE, enabling access to the Middle East market – both for Gaelic Laboratories and its marketing partners ...
Pharmabiz3d
US FDA accepts for review GSK’s Shingrix new prefilled syringe presentation
GSK plc, a global biopharma company, announced that the US Food and Drug Administration (FDA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s ...
Pharmabiz3d
IDMA plans extensive workshops on revised Schedule M to assist pharma MSMEs
With revision in extension of the deadline for implementing the revised Schedule M until December 31, 2025, the Indian Drug Manufacturers’ Association (IDMA) has announced plans to intensify its ...